Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

terminated117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

NCT01528735
completedphase_1

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects

NCT02182362
completedphase_1

Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

NCT02182323
completedphase_1

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

NCT02182336
terminatedphase_1

Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

NCT02182401
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01528735Phase 2

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Completed
NCT02182362Phase 1

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects

Completed
NCT02182323Phase 1

Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

Completed
NCT02182336Phase 1

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

Completed
NCT02182401Phase 1

Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

Terminated
NCT02182375Phase 1

Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6